Research programme: multiple kinase inhibitors - Celgene
Alternative Names: CC 001; CC 002; Multiple kinase inhibitors research programme - CelgeneLatest Information Update: 04 Dec 2019
At a glance
- Originator Celgene Corporation
- Class Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 07 May 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Nov 2003 Preclinical trials in Cancer in USA (unspecified route)